FOLOTYN ® (pralatrexate injection) is the first therapeutic to have been approved for peripheral T-cell lymphoma (PTCL), in September 2009 FOLOTYN net sales were approximately $50 million in 2011 ...

Allos Therapeutics announced the presentation of further data from its Phase 2b study of Folotyn (pralatrexate injection) relative to Tarceva (erlotinib, from Genentech) in patients with Stage IIIB/IV ...

Spectrum Pharmaceuticals confirmed in a filing that it received notification from the FDA of their early action granting accelerated approval of the company’s New Drug Application for Beleodaq for ...

HENDERSON, Nev. -- Spectrum Pharmaceuticals Inc. said Monday that the U.S. government extended the patent on its lymphoma drug Folotyn by five years. Spectrum said the patent will now expire on July ...

Vitamin supplementation can reduce certain side effects of Folotyn (pralatrexate), and the majority of patients are able to tolerate the full dose, concluded two safety studies in relapsed or ...

HENDERSON, Nev.--(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in ...

Allos Therapeutics anticipates a January commercial launch for Folotyn, the first and only drug currently approved by the FDA for relapsing or refractory peripheral T-cell lymphoma (rrPTCL). A ...

FOLOTYN (pralatrexate) 20mg/mL, 40mg/2mL injection by Allos Therapeutics Folotyn (pralatrexate injection) has been made available by Allos Therapeutics for use as a single agent for the treatment of ...

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced ...